Original research| Volume 101, ISSUE 9, P1485-1496, September 2020

Download started.


Efficacy and Safety of MT10107 (Coretox) in Poststroke Upper Limb Spasticity Treatment: A Randomized, Double-Blind, Active Drug-Controlled, Multicenter, Phase III Clinical Trial



      To compare the efficacy and safety of MT10107 (Coretox) with those of onabotulinum toxin A (Botox) in patients with poststroke upper limb spasticity


      Prospective, randomized, double-blind, active drug-controlled, multicenter, phase III clinical trial.


      Seven university hospitals in the Republic of Korea.


      Patients (N=220) with poststroke upper limb spasticity.


      All participants received a single injection of either MT10107 (Coretox group) or onabotulinum toxin A (Botox group).

      Main Outcome Measures

      The primary outcome was change in wrist flexor spasticity from baseline to week 4, which was assessed using the modified Ashworth scale (MAS). The secondary outcomes were MAS scores for wrist, elbow, and finger flexors; percentage of treatment responders (response rate); Disability Assessment Scale (DAS) score, and global assessment of treatment. Safety was evaluated based on adverse events, vital signs, physical examination findings, and laboratory test results. The efficacy and safety were evaluated at 4, 8, and 12 weeks postintervention.


      The primary outcome was found to be −1.32±0.69 and −1.40±0.69 for the Coretox and Botox groups, respectively. MT10107 showed a non-inferior efficacy compared with onabotulinum toxin A, as the 95% confidence interval for between-group differences was −0.10 to 0.27 and the upper limit was less than the non-inferiority margin of 0.45. Regarding the secondary outcomes, MAS scores for all muscles and DAS scores showed a significant improvement at all time points in both groups, with no significant between-group difference. No significant between-group differences were observed regarding response rate, global assessment of treatment, and safety measures.


      MT10107 showed no significant difference in efficacy and safety compared with onabotulinum toxin A in poststroke upper limb spasticity treatment.


      List of abbreviations:

      BTX-A (botulinum toxin type A), CI (confidence interval), DAS (Disability Assessment Scale), FAS (full analysis set), HSA (human serum albumin), MAS (modified Ashworth Scale), PPS (per protocol set)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Archives of Physical Medicine and Rehabilitation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sommerfeld D.K.
        • Gripenstedt U.
        • Welmer A.K.
        Spasticity after stroke: an overview of prevalence, test instruments, and treatments.
        Am J Phys Med Rehabil. 2012; 91: 814-820
        • Watkins C.L.
        • Leathley M.J.
        • Gregson J.M.
        • Moore A.P.
        • Smith T.L.
        • Sharma A.K.
        Prevalence of spasticity post stroke.
        Clin Rehabil. 2002; 16: 515-522
        • Ganapathy V.
        • Graham G.D.
        • DiBonaventura M.D.
        • Gillard P.J.
        • Goren A.
        • Zorowitz R.D.
        Caregiver burden, productivity loss, and indirect costs associated with caring for patients with poststroke spasticity.
        Clin Interv Aging. 2015; 10: 1793-1802
        • Sun L.C.
        • Chen R.
        • Fu C.
        • et al.
        Efficacy and safety of botulinum toxin type a for limb spasticity after stroke: a meta-analysis of randomized controlled trials.
        Biomed Res Int. 2019; 2019: 8329306
        • Dong Y.
        • Wu T.
        • Hu X.
        • Wang T.
        Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis.
        Eur J Phys Rehabil Med. 2017; 53: 256-267
        • Rosales R.L.
        • Chua-Yap A.S.
        Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity.
        J Neural Transm (Vienna). 2008; 115: 617-623
        • Frevert J.
        • Dressler D.
        Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?.
        Biologics. 2010; 4: 325-332
        • Walker T.J.
        • Dayan S.H.
        Comparison and overview of currently available neurotoxins.
        J Clin Aesthet Dermatol. 2014; 7: 31-39
        • Oh H.M.
        • Park J.H.
        • Song D.H.
        • Chung M.E.
        Efficacy and safety of a new botulinum toxin type a free of complexing proteins.
        Toxins (Basel). 2015; 8: 4
        • Bohannon R.W.
        • Smith M.B.
        Interrater reliability of a modified Ashworth scale of muscle spasticity.
        Phys Ther. 1987; 67: 206-207
        • Kanovsky P.
        • Slawek J.
        • Denes Z.
        • et al.
        Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity.
        Clin Neuropharmacol. 2009; 32: 259-265
        • Nam H.S.
        • Park Y.G.
        • Paik N.J.
        • et al.
        Efficacy and safety of NABOTA in post-stroke upper limb spasticity: a phase 3 multicenter, double-blinded, randomized controlled trial.
        J Neurol Sci. 2015; 357: 192-197
        • Do K.H.
        • Chun M.H.
        • Paik N.J.
        • et al.
        Safety and efficacy of letibotulinumtoxinA(BOTULAX®) in treatment of post stroke upper limb spasticity: a randomized, double blind, multi-center, phase III clinical trial.
        Clin Rehabil. 2017; 31: 1179-1188
        • Brashear A.
        • Zafonte R.
        • Corcoran M.
        • et al.
        Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity.
        Arch Phys Med Rehabil. 2002; 83: 1349-1354
        • Simpson D.M.
        • Alexander D.N.
        • O'Brien C.F.
        • et al.
        Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial.
        Neurology. 1996; 46: 1306-1310
        • Brashear A.
        • Gordon M.F.
        • Elovic E.
        • et al.
        Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke.
        N Engl J Med. 2002; 347: 395-400
        • Childers M.K.
        • Brashear A.
        • Jozefczyk P.
        • et al.
        Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke.
        Arch Phys Med Rehabil. 2004; 85: 1063-1069
        • Slawek J.
        • Bogucki A.
        • Reclawowicz D.
        Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens.
        Neurol Sci. 2005; 26: 32-39
        • Jost W.H.
        • Hefter H.
        • Reissig A.
        • Kollewe K.
        • Wissel J.
        Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: results of the German-Austrian open-label post-marketing surveillance prospective study.
        J Neurol Sci. 2014; 337: 86-90
        • Seo H.G.
        • Paik N.J.
        • Lee S.U.
        • et al.
        Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity: a multicenter randomized controlled trial.
        PLoS One. 2015; 10e0128633
        • Simpson D.M.
        • Gracies J.M.
        • Yablon S.A.
        • Barbano R.
        • Brashear A.
        Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study.
        J Neurol Neurosurg Psychiatry. 2009; 80: 380-385
        • Wolf S.L.
        • Milton S.B.
        • Reiss A.
        • Easley K.A.
        • Shenvi N.V.
        • Clark P.C.
        Further assessment to determine the additive effect of botulinum toxin type A on an upper extremity exercise program to enhance function among individuals with chronic stroke but extensor capability.
        Arch Phys Med Rehabil. 2012; 93: 578-587
        • Meythaler J.M.
        • Vogtle L.
        • Brunner R.C.
        A preliminary assessment of the benefits of the addition of botulinum toxin a to a conventional therapy program on the function of people with longstanding stroke.
        Arch Phys Med Rehabil. 2009; 90: 1453-1461
        • Foley N.
        • Pereira S.
        • Salter K.
        • et al.
        Treatment with botulinum toxin improves upper-extremity function post stroke: a systematic review and meta-analysis.
        Arch Phys Med Rehabil. 2013; 94: 977-989
        • Intercollegiate Stroke Working Party
        National clinical guideline for stroke. Vol 20083.
        Citeseer, 2012
        • Ozcakir S.
        • Sivrioglu K.
        Botulinum toxin in poststroke spasticity.
        Clin Med Res. 2007; 5: 132-138